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Abstract 
Background 
Development of interventions that address psychosocial and existential distress in people 
with motor neurone disease (MND) or that alleviate caregiver burden in MND family carers 
have often been suggested in the research literature. Dignity therapy, which was developed to 
reduce psychosocial and existential distress at the end of life, has been shown to benefit 
people dying of cancer and their families. These results cannot be applied to people with 
MND. The objectives of this study are to assess the feasibility, acceptability and potential 
effectiveness of dignity therapy to enhance the end of life experience for people with motor 
neurone disease and their family carers. 
Methods/design 
This is a cross-sectional study utilizing a single treatment group and a pre/post test design. 
The study population will comprise fifty people diagnosed with MND and their nominated 
family carers. Primarily quantitative outcomes will be gathered through measures assessed at 
baseline and at approximately one week after the intervention. Outcomes for participants 
include hopefulness, spirituality and dignity. Outcomes for family carers include perceived 
caregiver burden, hopefulness and anxiety/depression. Feedback and satisfaction with the 
intervention will be gathered through a questionnaire. 
Discussion 
This detailed research will explore if dignity therapy has the potential to enhance the end of 
life experience for people with MND and their family carers, and fill a gap for professionals 
who are called on to address the spiritual, existential and psychosocial needs of their MND 
patients and families. 
Trial registration 
ACTRN Trial Number: ACTRN12611000410954 
Keywords 
Motor neurone disease, Amyotrophic lateral sclerosis, Palliative care, Existential distress, 
Family carers, Dignity therapy 
Background 
As a result of elevated interest in hastened death at the end of life by people with motor 
neurone disease (MND), also known as amyotrophic lateral sclerosis (ALS), numerous 
studies have examined factors that affect quality of life, psychological health, and end-of-life 
distress in this population. Findings indicate that quality of life in MND-diagnosed 
individuals is independent of physical decline [1,2]; that interest in hastened death is 
correlated with hopelessness [3,4]; and that MND patients with higher levels of spirituality 
and sense of meaning experience less end of life distress [5,6]. This research has resulted in a 
call to develop psychosocial interventions for use with the MND population that will bolster 
hopefulness, spirituality, and meaning [7,8]; however, very little work has been done to 
develop and implement such interventions. 
MND is a family disease, and family carers carry an exceptional burden by providing a high 
level of care, often for the duration of the illness. Family carers of people with MND are 
more depressed than people with MND overall [9]. As time goes on and dependency 
increases, family carers exhibit increasing levels of distress symptoms [10,11]. Studies on the 
quality of life in MND family carers suggests that perceived caregiver burden can be 
alleviated by finding positive meaning [12,13] and by supporting a sense of hope [14]. 
Dignity therapy, a brief psychotherapeutic intervention based on empirical research into the 
concept of dignity at the end of life [15], has proven successful at increasing hope, sense of 
meaning and will to live in a palliative care population, where most patients had cancer 
diagnoses. Dignity therapy offers people with terminal illness the opportunity to create a 
generativity document. In a recorded interview guided by a counsellor or health care 
professional, the participant is invited to recount aspects of their life they want remembered, 
find meaning and purpose to their life, and express final words or advice. The interview is 
transcribed and edited, and a final dignity therapy transcript is returned to the participant to 
share with others as they wish. 
A pilot study of dignity therapy produced positive results for participants and family 
members. A heightened sense of dignity was reported in 76% of participants, an increased 
sense of purpose was reported by 68%, an increased sense of meaning was reported by 67%, 
and 47% reported an increased will to live [16]. A recent randomised controlled trial reported 
similar outcomes [17]. In the pilot study, family members were also positive about the 
intervention, with 95% reporting they would recommend dignity therapy, 78% reporting that 
it helped them during their time of grief, and 77% believing the document would be a 
continuing source of comfort [18]. 
Nonetheless, because these studies both utilized a primarily cancer population, the results are 
not transferable to people with MND. Ability to communicate, cognitive acuity, stage of 
illness, baseline levels of distress and demographic features are some of the factors that may 
vary in this population and make implementation of dignity therapy difficult. The delivery of 
the intervention may require modification, i.e. to be performed at an earlier stage in the 
disease process or by utilizing assisted communication methods. Therefore, feasibility testing 
of dignity therapy with the an MND specific population is warranted [19,20]. 
Moreover, while the previous dignity therapy study focused on the intervention’s positive 
influence on the bereavement experience of family members, it did not look at how the 
intervention may affect the carer during the caring experience. 
Aims and objectives 
The aims of this study are to assess the feasibility, acceptability and potential effectiveness of 
dignity therapy to enhance the end of life experience for people with MND and their family 
carers. The specific objectives are to: 
a) Determine whether dignity therapy is likely to increase hope, meaning and dignity in 
people with MND. 
b) Determine whether dignity therapy is likely to increase hope, and decrease anxiety, 
depression, and perceived burden in family carers of people with MND. 
c) Determine whether dignity therapy is acceptable to people with MND and their family 
carers. 
d) Determine whether it is feasible to provide dignity therapy to people with MND. 
e) Pilot methods for a future randomized controlled trial. 
Methods 
Study design 
This is a cross-sectional study utilizing a single treatment group and a repeated measures 
pre/post test design. A control group is not being utilized due to 1) the small MND population 
available in Western Australia 2) access issues to people with MND, and 3) the fact that 
dignity therapy (nor any other psychosocial intervention) has yet been tried with this 
palliative care population and the feasibility of dignity therapy needs to be tested before 
proceeding to an RCT. The study design has been modelled to reduce bias and increase 
validity where possible. For example, the short duration of the intervention coupled with 
utilizing a single post-testing point one week after the intervention will minimize 
confounding variables. 
Ethical approval 
This study has been approved by the Curtin University Human Research Ethics Committee 
(19/2011). 
Participants 
The sample will comprise 50 adults diagnosed with MND who are registered with the MND 
Association of Western Australia. A second group will consist of up to 50 family carers of 
the participants. 
People with MND 
Inclusion criteria 
Persons with a diagnosis of MND aged 18 and over who are able to communicate in English 
are included in the study. As this is a feasibility study, participants who are unable to 
communicate verbally may participate if they are able to utilize an assisted communication 
method. Communication issues will be explored and reported in the findings. There is no 
selection criteria based on stage of the disease as MND is a fatal disease with no hope of 
remission making an end-of-life intervention appropriate at any time after diagnosis. 
Participants will not be screened for existential or psychosocial distress; however, these will 
be assessed at baseline. 
Exclusion criteria 
Participants who are unable to provide informed consent, either due to cognitive issues or 
illness severity will be excluded. 
Family carers 
A family carer of each participant will be invited to take part in the study, comprising a 
second research population of up to 50 family carers. A family carer is defined as the person 
indicated by the participant as the primary family carer. The family carer must be at least 18 
years of age, able to provide informed consent and able to communicate in English. If the 
family carer does not wish to participate, then the person with MND remains eligible to take 
part in the study. 
The intervention and study procedures 
The intervention will be administered by the researcher, a counselling psychologist 
undertaking a PhD by research at Curtin University in Western Australia. The researcher has 
been trained in dignity therapy at an intensive workshop by Professor Harvey Chochinov, 
who developed the intervention and who performed the empirical studies upon which the 
intervention is based. 
Recruitment will be undertaken through the MND Association of Western Australia 
(MNDAWA). MNDAWA will liaise directly with participants to protect the identity of 
MND-diagnosed individuals. Letters will be sent out to all members of MNDAWA and 
potential participants are identified when they telephone the researcher or return a copy of the 
letter expressing their interest. The researcher will first speak with the person with MND or 
family carer to elaborate further on the nature of the study and answer any questions. If the 
participant wishes to proceed, a meeting will be scheduled. If time permits, information 
sheets and consent forms will be mailed in advance of the meeting to provide time to consider 
the study and discuss their participation with family and health care providers. All meetings 
will occur at a time of the participant’s choosing and in their care environment. Since the 
participant’s condition can fluctuate, the timing of the contacts can be flexible and meetings 
rescheduled. The researcher will make detailed notes of these experiences in order to include 
information about timing issues in the findings. 
At the initial meeting, the researcher will review the participant and family carer information 
and consent forms with the participant/family carer dyad, check for understanding and 
answer any outstanding questions. Written consent will be obtained and MND participants 
will be tested for cognitive impairment that is significant enough to exclude them from the 
study. If the participant and family carer remain in the study, socio-demographic and health 
questionnaires and baseline measures will be collected from each. An appointment for the 
first dignity therapy session will be made, ideally within two to three days. The researcher 
will provide the participant a copy of the dignity therapy question framework so that they 
may begin reflecting on their responses. 
Dignity therapy question protocol 
  Tell me a little about your life history; particularly the parts that you either remember most 
or think are the most important? When did you feel most alive? 
  Are there specific things that you would want your family to know about you, and are 
there particular things you would want them to remember? 
  What are the most important roles you have played in life (family roles, vocational roles, 
community service roles, etc.)? Why were they so important to you, and what do you 
think you accomplished in those roles? 
  What are your most important accomplishments, and what do you feel most proud of? 
  Are there particular things you feel still need to be said to your loved ones or things that 
you would want to take time to say once again? 
  What are your hopes and dreams for your loved ones? 
  What have you learned about life that you would want to pass along to others? What 
advice or words of guidance would you wish to pass along to your son, daughter, husband, 
wife, parents, other(s)? 
  Are there words or perhaps even instructions that you would like to offer your family to 
help prepare them for the future? 
  In creating this permanent record are there other thing you would like included? 
  [16] at p. 5522. 
The next meeting is the primary dignity therapy session, where participants are invited to 
address and record themes, thoughts and feelings about themselves and their lives that they 
would like remembered. The question framework is flexible, and provides a guide for the 
researcher to shape the interview by following the participant’s cues. If the participant 
desires, a family carer may be present during the interview to provide emotional support and 
help facilitate the interview. If participants require a second or third interview session due to 
communication issues, fatigue, or the breadth of information they would like to share, these 
will be scheduled as soon as possible. 
After recording has finished, a verbatim transcript will be prepared (usually within 24–48 
hours). The researcher will shape the interview into a narrative using the learned dignity 
therapy editing method, which omits non-starters and irrelevant sections (such as 
interruptions) and tags content that needs to be clarified or perhaps omitted due to the harm it 
could inflict on recipients. Another appointment will be made with the participant as soon as 
practicable to read through and edit the transcript. In this session, the participant will be 
invited to make corrections, clarifications or additions as desired. In the final dignity therapy 
session, the final bound transcript is given to the participant. The participants may have as 
many copies of the document as they wish and share them with whoever they choose. 
Post-testing will occur with both the participant and family carer one week after the final 
dignity therapy document has been returned. To reduce response bias, post-testing 
questionnaires will be sent out and returned via mail. A research officer from the Western 
Australian Centre for Cancer and Palliative care will perform the post-testing if assistance is 
needed to complete the questionnaires. A single point of post-testing soon after completion of 
the sessions is planned in order to reduce moderating variables. Further, the possible 
immediate impact of the intervention is being examined for the purposes of this feasibility 
study and not the longevity of the outcomes, which can be assessed in future studies. A study 
design flow chart is shown in Figure 1. 
Figure 1 Study Design Flow Chart 
Measures and outcomes 
The measures chosen have been validated and are quick and easy to administer and use, in 
order to decrease the burden on the study population. Brief versions of the outcome measures 
have been selected where available. 
Primary outcome measure for people with MND 
The primary outcome measure is the participant’s sense of hopefulness. This will be assessed 
utilizing the Herth Hope Index [21,22], a validated instrument developed for use with the 
terminally ill. Distressed MND patients score higher on hopelessness than distressed cancer 
patients at the end of life [23], and interest in hastened death or suicidal ideation in the MND 
population has been shown to correlate with hopelessness [3,24], which indicates that the 
level of hopefulness a key factor of psychological distress in this disease population. 
Secondary outcome measures for people with MND 
Secondary outcome measures used to assess potential effectiveness include, 1) dignity, which 
will be measured with the Patient Dignity Inventory (PDI) [25], a validated measure which 
evolved directly from the empirical studies into dignity concerns in the terminally ill, and; 2) 
spiritual well-being, which will be measured with the Functional Assessment of Chronic 
Illness Therapy-Spiritual Well-Being Scale (FACIT-sp-12) [26], a validated measure 
showing strong internal reliability. To assess the acceptability of dignity therapy, a modified 
version of the dignity therapy Patient Feedback Questionnaire [17] is being utilized to collect 
information on the views, experiences and opinions of the participants about the intervention. 
To assess the feasibility of the intervention, data will be collected about the time taken to 
organize and conduct the dignity therapy sessions, any special accommodations made in the 
delivery of the intervention, deviations from the dignity therapy protocol, and reasons for 
non-completion. The researcher will also record, through the use of a journal, observations 
and experiences of delivering the intervention, including positive and negative participant 
responses. 
Primary outcome measure for family carers 
The primary outcome is the family carer’s sense of perceived burden, which will be measured 
through the Zarit Burden Inventory [27]. Research of caregiver burden in MND family carers 
has documented the considerable burden attached to caring for persons with MND [28,29]. 
Caregiver burden increases as patient function declines [30-32]. Studies indicate that MND 
caregiver burden can be alleviated by finding positive meaning [12,13] and by supporting a 
sense of hope [14]. It can be inferred that dignity therapy may impact hope and meaning, 
thereby alleviating caregiver burden. In the alternative, whether this intervention increases 
burden is a factor that also must be considered when evaluating its overall impact. 
Secondary outcome measures for family carers 
Secondary outcome measures used to assess the potential impact of dignity therapy on family 
carers includes 1) hopefulness, utilizing the Herth Hope Index [21]. The HHI has been used 
successfully in studies with family caregivers of terminally ill patients [33], and 2) anxiety 
and depression, which will be measured with the Hospital Anxiety and Depression Scale 
[34], an instrument often used with family caregivers showing strong reliability and validity. 
To assess the acceptability of dignity therapy to family carers, a modified version of the 
dignity therapy Family Feedback Questionnaire [17] is being utilized to collect information 
on the views, experiences and opinions of the family carers about the intervention. 
Demographic and health status 
Demographic and health status information collected from persons with MND will include 
disease specific health-related quality of life utilizing the Amyotrophic Lateral Sclerosis 
Assessment Questionnaire-5 [35], cognitive behavioural functioning utilizing the ALS 
Cognitive Behavioral Screen [36], age, gender, and health history. 
Demographic and health status information collected from family carers will include the level 
of disability of the care recipient utilizing the Amyotrophic Lateral Sclerosis Functional 
Rating Scale-R [37,38], cognitive behavioural functioning utilizing the ALS Cognitive 
Behavioral Screen [36], age, gender, relationship to the person with MND, caring hours per 
day, employment status, and health history. 
Analysis 
For summarizing purposes, descriptive statistics will be obtained for demographic variables. 
To assess the possible impact of the intervention on the psychosocial and existential concerns 
of the participant and family carer, pre and post intervention comparisons for each outcome 
variable will be carried out using Wilcoxon’s signed rank-sum tests, given that the main 
outcome variable measured will not be normally distributed [16]. Spearman’s rank 
correlation coefficient will be calculated to assess the possible correlation between variables 
of interest. It is anticipated that there will be a post-intervention improvement on all 
psychosocial measures for both the participant and family carer after the dignity therapy 
intervention. Open-ended responses in feedback questionnaires will be coded and analysed 
using descriptive statistics. The IBM SPSS version 20 statistical software package will be 
used for all analyses. A p value less than 0.05 is considered as statistically significant. 
Discussion 
Several studies, as well as MND practice guidelines, suggest the need to develop and utilize 
interventions that will support hopefulness, a sense of meaning, and dignity in order to 
alleviate psychosocial and existential distress in persons with MND [7,8]. Despite this, very 
little has been done to develop or implement such interventions. In fact, an extensive 
literature search completed for this study revealed there were no psychosocial interventions 
specifically designed or tailored to alleviate existential distress and improve the quality of life 
of persons with MND. This research will begin to fill this gap, providing a possible solution 
to a concern about this specific population, as well as continue to advance the overall focus of 
alleviating psychosocial distress at the end of life, an area of palliative care which has been 
widely acknowledged as being in need of improvement. 
This study will determine if dignity therapy is likely to be effective in enhancing the end of 
life experience for both people with MND and their family carers, if it is acceptable to people 
with MND and their family carers, and if it is feasible to offer the intervention to this 
population. It will explore what allowances or modifications might need to be made to deliver 
the intervention to people who are sometimes unable to communicate verbally. It will provide 
a preliminary examination of how cognitive or neurobehavioral issues encountered in persons 
with MND might affect the intervention, including the completion and sharing of a 
generativity document that reflects a true sense of the person with MND. Finally, if the 
intervention is unsuccessful, this study will determine what factors contributed to a negative 
outcome, as well as any unexpected consequences to persons with MND or their families. 
This research has implications for psychological and health care professionals who work with 
people with motor neurone disease and other neurological disorders, as well as those who 
work in palliative care settings. Both are often called on to address the spiritual, existential 
and psychosocial needs in their patients. If dignity therapy proves to be effective, it could be 
a relatively brief and easy to administer intervention that could be made available to people 
with MND. This study has the potential to provide a precise intervention to ameliorate 
psychosocial and existential distress, as well as improve the quality of care provided to 
people with MND and their family carers. 
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